drugset / Trial / NCT01833143
Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
Phase 2
Completed
17 enrolled
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the drug Bortezomib to see how well it works. The investigators want to find out what effects, good or bad, it has on patients with a limited smoking history or who have a specific mutation associated with their lung cancer.
Timeline
- Start
- 2013-04-11
- Primary completion
- 2019-08-28
- Completion
- 2019-08-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Background | Acyclovir | Small molecule | 400 mg | — |